CONCLUSION
Appendiceal disease in hematopoietic stem cell transplant patients is rarely reported and there is little guidance in management. Our patients were all effectively treated for their appendiceal disease. Based on our experience, in pre-transplant patients who present with appendiceal disease there is a need to balance the risks and benefits of definitive surgical resolution of the appendiceal disease. Pre-transplant patients with severe cytopenias from chemotherapy should be considered to receive a trial of medical therapy with plan for appendectomy after recovery but prior to transplant. Appendicitis in pre-engraftment patients may be confounded by alternative infectious process or mucositis. In these patients a trial of medical therapy may be considered with subsequent evaluation after engraftment. Post-transplant patients on immunosuppression may receive a trial of medical therapy with plan for appendectomy after completion of immunosuppression.